The report contains ten-year analysis with the following sections
contact us for pricing
Check out our sample pages |
Many companies now available
Search to find companies of interest
read summary of their published patent
the company report contains more information
medarex | 971 |
amgen | 285 |
e. r. squibb & sons | 251 |
bristol-myers squibb company | 194 |
pfizer | 117 |
ono pharmaceutical company | 66 |
oxford biotherapeutics | 31 |
lowy, israel | 30 |
kyowa hakko kirin company | 18 |
biolex therapeutics | 14 |
medarex | 167 |
pfizer | 18 |
bristol-myers squibb company | 14 |
amgen | 13 |
biolex therapeutics | 5 |
peter brams | 4 |
mcgee, danny, p., c. | 4 |
lowy, israel | 3 |
cell genesys | 3 |
oxford genome sciences (uk) | 3 |
Title of patent family (most common patent title) |
Family members |
Filing year |
---|---|---|
human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer … 🛈 | 71 | 2005 |
binding molecules to the human ox40 receptor | 70 | 2007 |
human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | 69 | 2003 |
therapeutic human anti-il-1r1 monoclonal antibody | 64 | 2002 |
antibodies against clostridium difficile toxins and uses thereof | 58 | 2004 |
human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | 55 | 2008 |
human antibodies that bind cxcr4 and uses thereof | 51 | 2006 |
antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | 48 | 2009 |
human monoclonal antibodies to programmed death ligand 1 (pd-l1) | 47 | 2005 |
human anti-b7rp1 neutralizing antibodies | 46 | 2005 |